Literature DB >> 11336351

A human lymphocyte based ex vivo assay to study the effect of drugs on P-glycoprotein (P-gp) function.

D A Parasrampuria1, M V Lantz, L Z Benet.   

Abstract

PURPOSE: The effect of drugs on P-glycoprotein (P-gp) is normally studied in transfected or overexpressing cell lines derived from tumor cells or animal tissue. We wanted to develop an assay using normal healthy human tissue to study and characterize the drug-transporter interaction.
METHODS: Lymphocytes were isolated from healthy human blood. The effect of inhibitors of P-gp (cyclosporine, tacrolimus, verapamil, quinidine, vinblastine) and of other transporters (indomethacin, probenecid, sulfinpyrazone) on intracellular accumulation of rhodamine 123 was evaluated by flow cytometry.
RESULTS: The efflux of rhodamine 123 was inhibited by P-gp inhibitors in a saturable, concentration-dependent manner. The potency of inhibition of P-gp was cyclosporine > tacrolimus > quinidine > verapamil > vinblastine. Vinblastine inhibited P-gp at lower concentrations, whereas at high concentrations, there was an activation of rhodamine 123 efflux from lymphocytes. The multidrug resistance associated protein (MRP) inhibitors, sulfinpyrazone and probenecid, did not have any significant effect on intracellular accumulation of rhodamine 123, but indomethacin caused a concentration-dependent increase in retention of rhodamine 123, indicating the involvement of other uncharacterized transporters.
CONCLUSIONS: Lymphocytes can serve as a model tissue for studying modulation of P-gp activity by drugs. Both inhibitors and inducers of P-gp activity can be evaluated.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11336351     DOI: 10.1023/a:1011070509191

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  22 in total

1.  Grapefruit juice activates P-glycoprotein-mediated drug transport.

Authors:  A Soldner; U Christians; M Susanto; V J Wacher; J A Silverman; L Z Benet
Journal:  Pharm Res       Date:  1999-04       Impact factor: 4.200

2.  Efflux of rhodamine from CD56+ cells as a surrogate marker for reversal of P-glycoprotein-mediated drug efflux by PSC 833.

Authors:  R Robey; S Bakke; W Stein; B Meadows; T Litman; S Patil; T Smith; T Fojo; S Bates
Journal:  Blood       Date:  1999-01-01       Impact factor: 22.113

Review 3.  The mechanism of ATP-dependent multidrug transport by P-glycoprotein.

Authors:  A B Shapiro; V Ling
Journal:  Acta Physiol Scand Suppl       Date:  1998-08

Review 4.  How does P-glycoprotein recognize its substrates?

Authors:  K Ueda; Y Taguchi; M Morishima
Journal:  Semin Cancer Biol       Date:  1997-06       Impact factor: 15.707

Review 5.  Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy.

Authors:  V J Wacher; C Y Wu; L Z Benet
Journal:  Mol Carcinog       Date:  1995-07       Impact factor: 4.784

Review 6.  Biochemistry of multidrug resistance mediated by the multidrug transporter.

Authors:  M M Gottesman; I Pastan
Journal:  Annu Rev Biochem       Date:  1993       Impact factor: 23.643

7.  Ranking of P-glycoprotein substrates and inhibitors by a calcein-AM fluorometry screening assay.

Authors:  F Tiberghien; F Loor
Journal:  Anticancer Drugs       Date:  1996-07       Impact factor: 2.248

Review 8.  Multidrug transporters from bacteria to man: similarities in structure and function.

Authors:  H W van Veen; W N Konings
Journal:  Semin Cancer Biol       Date:  1997-06       Impact factor: 15.707

9.  Transport properties of the multidrug resistance-associated protein (MRP) in human tumour cells.

Authors:  Z Holló; L Homolya; T Hegedüs; B Sarkadi
Journal:  FEBS Lett       Date:  1996-03-25       Impact factor: 4.124

10.  Indomethacin-mediated reversal of multidrug resistance and drug efflux in human and murine cell lines overexpressing MRP, but not P-glycoprotein.

Authors:  M P Draper; R L Martell; S B Levy
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

View more
  5 in total

1.  Expression of multidrug resistance P-glycoprotein on lymphocytes from nephrotic children treated with cyclosporine A and ACE-inhibitor.

Authors:  Anna Wasilewska; Walentyna Zoch-Zwierz; Mirosława Pietruczuk
Journal:  Eur J Pediatr       Date:  2006-09-22       Impact factor: 3.183

2.  Induction of P-glycoprotein in lymphocytes by carbamazepine and rifampicin: the role of nuclear hormone response elements.

Authors:  Andrew Owen; Chris Goldring; Paul Morgan; B Kevin Park; Munir Pirmohamed
Journal:  Br J Clin Pharmacol       Date:  2006-08       Impact factor: 4.335

3.  P-glycoprotein overexpression in bone marrow-derived multipotent stromal cells decreases the risk of steroid-induced osteonecrosis in the femoral head.

Authors:  Ning Han; Zengchun Li; Zhengdong Cai; Zuoqin Yan; Yingqi Hua; Chong Xu
Journal:  J Cell Mol Med       Date:  2016-07-11       Impact factor: 5.310

Review 4.  Targeting Glycoproteins as a therapeutic strategy for diabetes mellitus and its complications.

Authors:  Rozita Naseri; Seyed Jafar Navabi; Zeinab Samimi; Abhay Prakash Mishra; Manisha Nigam; Harish Chandra; Ahmed Olatunde; Habibu Tijjani; Raquel P Morais-Urano; Mohammad Hosein Farzaei
Journal:  Daru       Date:  2020-01-31       Impact factor: 3.117

5.  New fluphenazine analogues as inhibitors of P-glycoprotein in human lymphocyte cultures.

Authors:  Agata Jaszczyszyn; Kazimierz Gąsiorowski; Piotr Swiątek; Wiesław Malinka; Katarzyna Cieślik-Boczula; Joanna Petrus; Bogusława Czarnik-Matusewicz
Journal:  Contemp Oncol (Pozn)       Date:  2012-09-29
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.